The FDA's Use of Adverse Publicity

DSpace/Manakin Repository

The FDA's Use of Adverse Publicity

Citable link to this page

. . . . . .

Title: The FDA's Use of Adverse Publicity
Author: Liu, Leon
Citation: The FDA's Use of Adverse Publicity (1998 Third Year Paper)
Full Text & Related Files:
Abstract: Of all the regulatory tools available to the FDA in fulfilling its duties, one of the most contentious and problematic is its use of adverse publicity. Whether it is because of its quasi-statutory status, the questionable legality of its often unregulated use, or its great potential for harm to those it is directed at, there are many who object to the use of adverse publicity by the FDA. However, one cannot deny its significant effectiveness as a regulatory tool and its often necessary and justified use in protecting the public health and safety. The purpose of this paper, then, is to explore the FDA's use of adverse publicity and the issues and conflicts that arise as a result.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965582

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters